Tesamorelin: What the Published GHRH-Analogue Research Reports

Tesamorelin is a stabilised analogue of human growth hormone-releasing hormone (GHRH[1-44]) that has been studied primarily in human randomized controlled trials and in secondary analyses of those trials [1][2]. In a frequent-sampling study of 13 healthy men, short-term administration increased mean overnight GH, average log GH peak area, and basal GH secretion, and raised IGF-1, while fasting glucose and insulin-stimulated glucose uptake measured by euglycemic hyperinsulinemic clamp were not significantly changed [1]. That study is the principal human pharmacodynamic characterisation of how the compound alters endogenous pulsatile GH secretion rather than supplying exogenous GH [1]. The largest body of human data concerns body composition in people with HIV and excess abdominal fat. A pooled analysis of two multicentre, double-blind, placebo-controlled phase 3 trials enrolling 806 participants on antiretroviral therapy reported a significant decrease in visceral adipose tissue measured by computed tomography at week 26 relative to placebo, with no significant change in abdominal subcutaneous adipose tissue, alongside decreases in triglycerides and the cholesterol-to-HDL ratio and an increase in IGF-1 [2]. A systematic review and meta-analysis of four randomized controlled trials totalling 909 participants reported pooled reductions in visceral adipose tissue, waist circumference, and trunk fat, an increase in lean body mass, and a small reduction in total cholesterol, while also noting growth hormone-related adverse effects and a higher discontinuation rate in treated arms [3]. A later randomized, double-blind analysis restricted to 38 participants receiving integrase inhibitor-based regimens reported declines over 12 months in visceral fat by MRI, hepatic fat fraction by proton magnetic resonance spectroscopy, and trunk-to-appendicular fat ratio by DXA, with a similar frequency of adverse events including hyperglycemia between arms [4]. Review articles summarising this literature describe GHRH analogues as the interventions most consistently associated with reductions in visceral adipose tissue in HIV-associated lipohypertrophy, while noting that optimal treatment duration and long-term metabolic and cardiovascular outcomes remain unresolved [5][6]. Parallel human trials were conducted in abdominally obese adults with reduced GH secretion. In a 12-month randomized, double-blind, placebo-controlled study of 60 such participants, visceral adipose tissue, carotid intima-media thickness, log C-reactive protein, and triglycerides changed significantly versus placebo, subcutaneous adipose tissue did not change significantly, IGF-1 increased, and no changes were seen in fasting glucose, 2-hour glucose, or glycated hemoglobin [7]. Within a related 12-month trial in 39 obese adults with reduced GH secretion, increases in IGF-1 correlated with phosphocreatine recovery parameters measured by 31P magnetic resonance spectroscopy, which the authors interpreted as suggestive of mitochondrial function [8]. A two-week interventional study in 13 men found that total adiponectin correlated with endogenous GH pulsatility parameters at baseline, but that neither total nor high-molecular-weight adiponectin changed significantly with short-term treatment [9]. A randomized placebo-controlled trial in people with HIV and nonalcoholic fatty liver disease generated several mechanistic secondary analyses using paired liver biopsies. Gene set enrichment analysis of those biopsies reported increased hepatic expression of gene sets involved in oxidative phosphorylation and decreased expression of gene sets relating to inflammation, tissue repair, and cell division in the treated arm, with changes correlating with a fibrosis-related gene score [10]. A targeted plasma proteomic follow-up in the same cohort reported reductions in VEGFA, TGFB1, and CSF1 versus placebo, with reductions in VEGFA and CSF1 correlating with change in NAFLD activity score and reductions in TGFB1 and CSF1 correlating with gene-level fibrosis score [11]. A proteomic analysis of 92 immune- and chemotaxis-related biomarkers in 61 participants from the same trial reported significant decreases in 13 circulating proteins, including chemokines, cytokines, and T-cell-associated molecules, with no proteins increasing, alongside a concordant down-regulation signal in targeted liver transcriptomics [12]. Analyses of hepatic IGF1 and IGF-binding protein expression in the same population described relationships between these transcripts and steatosis, NAFLD activity score, fibrosis, and glycemic measures, and reported that GHRH administration increased circulating IGFBP-1 and IGFBP-3 while decreasing IGFBP-2 and IGFBP-6 [13]. A separate proteomic analysis from the same trial characterised the baseline circulating signature of hepatic fibrosis, identifying up-regulation of tissue repair and immune response pathways independent of treatment assignment [14]. Cognitive endpoints have been examined in older adults. A 20-week randomized, double-blind, placebo-controlled trial in 152 adults aged 55 to 87, including 66 with mild cognitive impairment, reported a treatment effect on a composite cognitive outcome driven largely by executive function measures, a 117% increase in IGF-1, a 7.4% reduction in percent body fat, an increase in fasting insulin within the normal range in the MCI subgroup, and adverse events reported by 68% of treated versus 36% of placebo participants [15]. A magnetic resonance spectroscopy substudy of 30 participants from that trial reported increased GABA levels across three sampled brain regions, increased NAAG in dorsolateral frontal cortex, and decreased myo-inositol in posterior cingulate, with no change in glutamate and no significant association between neurochemical and cognitive changes [16]. A later 10-week double-blind pilot trial in 22 adults with cognition ranging from normal to mild cognitive impairment found no significant groupwise changes in body composition, fatigue, sleep, physical performance, glucose tolerance, cognition, or brain morphometry, with only exploratory machine-learning analyses suggesting regional connectivity differences [17]. Tesamorelin also appears in the analytical and regulatory literature. It is listed among GHRH analogues prohibited by the World Anti-Doping Agency, and laboratory method-development work has compared magnetic bead surface chemistries for immunopurification of these peptides from human urine prior to liquid chromatography-high resolution mass spectrometry, reporting a limit of detection of 0.2 ng/mL [18]. A narrative review of peptides marketed as "research compounds" places GHRH analogues including tesamorelin in the highest evidence tier, having regulatory-grade randomized trial data, while noting that reported adverse effects across this peptide class span endocrine and metabolic disturbances, fluid retention, musculoskeletal symptoms, and injection-site reactions, and that product composition in unregulated supply chains is uncertain [19]. Taken together, the retrieved literature is overwhelmingly human and trial-based; no animal or cell-culture studies of the compound appear in this set, and the mechanistic findings described above are secondary analyses of human trial specimens rather than independent preclinical work [10][11][12].